Lucatumumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Identifiers | |
| CAS Number | 903512-50-5  |
| ATC code | none |
| UNII | P0EP9VFC4R  |
| KEGG | D08942 |
| Chemical data | |
| Molecular mass | 146 kg/mol |
| (what is this?) (verify) |
|
Lucatumumab is a human monoclonal antibody[1] being investigated for the treatment of various types of cancer like multiple myeloma,[2] non-Hodgkin's or Hodgkin's lymphoma.[3]
This drug was developed by Novartis Pharmaceuticals Corp.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ↑ Clinical trial number NCT00231166 at ClinicalTrials.gov
- ↑ Clinical trial number NCT00670592 at ClinicalTrials.gov
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Novartis
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
